University of California San Francisco
Give to UCSF
A physically and mentally active lifestyle confers resilience to frontotemporal dementia, even in people whose genetic profile makes the eventual development of the disease virtually inevitable.
We are entering an era of brain-machine interfaces and genome-editing technology. When we can govern the very biology that makes us who we are, what will it mean to be human?
Brain imaging of pathological tau-protein reliably predicts the location of future brain atrophy in Alzheimer’s patients a year or more in advance.
A drug that once helped obese adults lose weight, but was withdrawn from the market due to heart risks, may be safe and effective for children with a life-threatening seizure disorder called Dravet syndrome.
From international awards for high-caliber research to groundswell movements for social change, this past year was an eventful one for the UCSF community.
Patients with ambiguous neurological symptoms, but no diagnosis, frequently go from specialist-to-specialist over a protracted period of time. The new clinic’s goal is to fast-forward the time lapses between appointments by enabling pre-diagnostic screening and expert consultations to take place in a single visit.
The Global Brain Health Institute and the Alzheimer Research Center (Havana)—in collaboration with the UCSF Memory and Aging Center, Cuba Platform; and the Medical University of Havana—announced the launch of a new Spanish language video series for dementia caregivers, “Conversando con los Cuidadores.”
With a $106 million gift from the Weill Family Foundation, UC Berkeley, UC San Francisco, and the University of Washington have launched the Weill Neurohub to speed the development of new therapies for diseases and disorders that affect the brain and nervous system.
Adam L. Boxer answers questions about the potential of "basket trials" to accelerate drug development for dementia and neurodegenerative disease.
